Deaths; cause of death (extensive list), age and sex
| Sex | Age | Causes of death | Periods | Deaths (number) |
|---|---|---|---|---|
| Total male and female | Total | A81 Atypical virus inf. of cent. nerv.. | 2024* | 51 |
| Total male and female | Total | B20 Human immunodeficiency virus [HIV].. | 2024* | 5 |
| Total male and female | Total | B21 Human immunodeficiency virus [HIV].. | 2024* | 5 |
| Total male and female | Total | B22 Human immunodeficiency virus [HIV].. | 2024* | 2 |
| Total male and female | Total | B23 Human immunodeficiency virus [HIV].. | 2024* | 4 |
| Total male and female | Total | J11 Influenza, virus not identified | 2024* | 403 |
| Total male and female | Total | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 1,225 |
| Total male and female | 0 year | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 0 year | B20 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 0 year | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 0 year | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 0 year | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 0 year | J11 Influenza, virus not identified | 2024* | 0 |
| Total male and female | 0 year | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 0 |
| Total male and female | 1 to 4 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 1 to 4 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 1 to 4 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 1 to 4 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 1 to 4 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 1 to 4 years | J11 Influenza, virus not identified | 2024* | 1 |
| Total male and female | 1 to 4 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 0 |
| Total male and female | 5 to 9 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 5 to 9 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 5 to 9 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 5 to 9 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 5 to 9 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 5 to 9 years | J11 Influenza, virus not identified | 2024* | 1 |
| Total male and female | 5 to 9 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 0 |
| Total male and female | 10 to 14 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 10 to 14 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 10 to 14 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 10 to 14 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 10 to 14 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 10 to 14 years | J11 Influenza, virus not identified | 2024* | 0 |
| Total male and female | 10 to 14 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 0 |
| Total male and female | 15 to 19 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 15 to 19 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 15 to 19 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 15 to 19 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 15 to 19 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 15 to 19 years | J11 Influenza, virus not identified | 2024* | 1 |
| Total male and female | 15 to 19 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 1 |
| Total male and female | 20 to 24 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 20 to 24 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 20 to 24 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 20 to 24 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 20 to 24 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 20 to 24 years | J11 Influenza, virus not identified | 2024* | 1 |
| Total male and female | 20 to 24 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 2 |
| Total male and female | 25 to 29 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 25 to 29 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 25 to 29 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 25 to 29 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 25 to 29 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 25 to 29 years | J11 Influenza, virus not identified | 2024* | 0 |
| Total male and female | 25 to 29 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 1 |
| Total male and female | 30 to 34 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 30 to 34 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 30 to 34 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 30 to 34 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 30 to 34 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 30 to 34 years | J11 Influenza, virus not identified | 2024* | 0 |
| Total male and female | 30 to 34 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 0 |
| Total male and female | 35 to 39 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 35 to 39 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 1 |
| Total male and female | 35 to 39 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 35 to 39 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 35 to 39 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 35 to 39 years | J11 Influenza, virus not identified | 2024* | 0 |
| Total male and female | 35 to 39 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 2 |
| Total male and female | 40 to 44 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 40 to 44 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 40 to 44 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 40 to 44 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 40 to 44 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 40 to 44 years | J11 Influenza, virus not identified | 2024* | 0 |
| Total male and female | 40 to 44 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 1 |
| Total male and female | 45 to 49 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 0 |
| Total male and female | 45 to 49 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 1 |
| Total male and female | 45 to 49 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 2 |
| Total male and female | 45 to 49 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 45 to 49 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 45 to 49 years | J11 Influenza, virus not identified | 2024* | 6 |
| Total male and female | 45 to 49 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 3 |
| Total male and female | 50 to 54 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 2 |
| Total male and female | 50 to 54 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 1 |
| Total male and female | 50 to 54 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 50 to 54 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 1 |
| Total male and female | 50 to 54 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 50 to 54 years | J11 Influenza, virus not identified | 2024* | 3 |
| Total male and female | 50 to 54 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 13 |
| Total male and female | 55 to 59 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 6 |
| Total male and female | 55 to 59 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 1 |
| Total male and female | 55 to 59 years | B21 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Total male and female | 55 to 59 years | B22 Human immunodeficiency virus [HIV].. | 2024* | 1 |
| Total male and female | 55 to 59 years | B23 Human immunodeficiency virus [HIV].. | 2024* | 1 |
| Total male and female | 55 to 59 years | J11 Influenza, virus not identified | 2024* | 7 |
| Total male and female | 55 to 59 years | U00-U99 Total COVID-19 (Coronavirus d.. | 2024* | 11 |
| Total male and female | 60 to 64 years | A81 Atypical virus inf. of cent. nerv.. | 2024* | 7 |
| Total male and female | 60 to 64 years | B20 Human immunodeficiency virus [HIV].. | 2024* | 0 |
| Source: CBS. | ||||
Table explanation
This table contains the number of deaths in the population of the Netherlands by underlying cause of death. The causes of death are shown according to the extensive list of 'three digit codes', by age and sex.
Since 2013 Statistics Netherlands is using Iris software for automatic coding for cause of death. This improved the international comparison of the data. The change in coding did cause a considerable shift in the statistic. Since 2013 the (yearly) ICD-10 updates are applied.
Data available from: 1996
Status of the figures:
The figures up untill 2023 are final, the figures of 2024 are provisional.
Changes as of July 3rd 2025:
The provisional figures for 2024 have been added.
Changes as of February 14th 2025:
For 2023 one death by 'Acute poliomyelitis (A80)' is moved to 'Sequelae of poliomyelitis (B91)'.
When will new figures be published?
The aim is to publish the final figures of 2024 in the fourth quarter of 2025.
Description topics
- Deaths